Pertuzumab/Trastuzumab is named as a drug or biological intervention in 3 clinical trials in our China trial register, 3 of which are recruiting. Lead sponsors include Peking Union Medical College (1), Fujian Medical University Union Hospital (1) and Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1). Registered phases: Phase 2 and Not applicable. Conditions studied include Salivary Gland Carcinoma; Precision Therapy; Breast Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05292742 | Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer, Adjuvant Therapy |
Phase 2 | Recruiting |
| NCT06145308 | Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (ClinicalTrials.gov ↗) Salivary Gland Carcinoma, Precision Therapy |
Phase 2 | Recruiting |
| NCT07095023 | Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer (ClinicalTrials.gov ↗) Breast Cancers |
Not applicable | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Salivary Gland Carcinoma | 1 |
| Precision Therapy | 1 |
| Breast Cancer | 1 |
| Adjuvant Therapy | 1 |
| Breast Cancers | 1 |
| Lead sponsor | Trials |
|---|---|
| Peking Union Medical College | 1 |
| Fujian Medical University Union Hospital | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| Register | Pertuzumab/Trastuzumab trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Pertuzumab/Trastuzumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Pertuzumab/Trastuzumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.